GE HealthCare has raised its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid solid demand across all of its business segments in Q3 2025.
Achieving revenues of $5.9bn in Q3, reflecting a 6% rise on Q3 2024, the imaging giant now expects profits of $4.51 to $4.63 per share, up from $4.43 at the low-end to $4.63 previously.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patient Care Solutions and Pharmaceutical Diagnostics rose by 6% and 20% in Q3 to $731m and $749m, respectively. However, the lion鈥檚 share of revenue was down to GE HealthCare鈥檚 Imaging and Advanced Visualisation Solutions, with revenues rising by 5% and 7% to around $2.34bn and $1.3bn, respectively.
During its post-earnings conference call, GE HealthCare鈥檚 CEO, Peter Arduini highlighted that the company鈥檚 鈥渟ynergistic portfolio鈥� of diagnostic imaging equipment, radiopharmaceuticals, artificial intelligence (AI), cloud, and software was giving it a competitive advantage in the imaging space.
Arduini added that strong commercial execution, with multiple large system deals in Q3, would drive almost $500m in future revenue, thereby further strengthening its ongoing growth momentum.
Earlier this month, GE HealthCare inked a , focused on early detection and advancing cancer care with imaging solutions and novel therapies such as theragnostics.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn September, GE HealthCare acquired AI-based brain imaging company icometrix to expand its magnetic resonance (MR) imaging capabilities for neurological disorders.
Arduini commented: 鈥淲ith the integration of icometrix technologies into our MR systems, we will strengthen our unique and comprehensive portfolio to support the full Alzheimer’s care pathway. This is a great example of our D3 strategy at work: smart devices and imaging, and drugs in PDX enabled by AI to create meaningful value for our customers and patients while driving sustainable growth for the company.鈥�
Arduini also highlighted that integrating technology like CaptionAI into its Vscan Air SL wireless handheld ultrasound system to provide real-time guidance for cardiac exams and upgrading its fleet of clinical subsystems into common platforms, had increased the margins of these new products compared to prior models.
Within the past six months, GE HealthCare has released software combining its own imaging functionalities with tools enabled by a platform developed by MIM Software, to enhance imaging workflows in indications including oncology and cardiology, and launched Vivid Pioneer, a new cardiovascular ultrasound system that integrates AI to enhance imaging speed and quality.
Asked about the company鈥檚 2026 growth outlook since projecting organic growth for FY25 of 3%, GE HealthCare鈥檚 CFO, James Saccaro, said as it looks to 2026, its expectation would be to 鈥済row faster鈥� than 3%.
